Please login to the form below

depression

This page shows the latest depression news and features for those working in and with pharma, biotech and healthcare.

Biogen signs $3.1bn deal with Sage for potential depression therapies

Biogen has bet up to $3.1bn on a series of potential depression and movement disorder therapies currently being developed by Sage Therapeutics. ... Scale for Depression (HAM-D) total score at day 15 compared to placebo.

Latest news

Acadia’s Nuplazid misses the mark in major depressive disorder trial

The drug failed to improve patient scores on the Hamilton Depression Rating Scale (HAMD-17) – a standard measure used for depression and the primary endpoint of the study. ... our earlier positive depression studies as we assess the next steps,” he
The best work in healthcare communications shines at virtual Communiqué Awards

6. Excellence in Multichannel Communications. Sponsored by Hanover. Winner: Breaking Depression – A Story of 40 Million Broken Pieces by Publicis Health for Janssen EMEA. ... Sponsored by Say Communications. Winner: Breaking Depression – A Story of
Trevena gets second go at FDA approval for pain drug

Some concluded there wasn’t enough data on side effects like respiratory depression compared to equivalent doses of current opioids such as morphine – even though oliceridine was specifically developed to reduce
Botox strength bolsters Allergan ahead of AbbVie takeover

A new approval in bipolar depression has contributed to the sales growth.
NICE knocks back J&J’s depression nasal spray Spravato

Cites clinical and pricing uncertainty as basis of rejection. Johnson &Johnson’s depression nasal spray Spravato has been hit with a rejection by the UK’s National Institute for Health and ... depression compared to placebo and an oral antidepressant.

More from news
Approximately 28 fully matching, plus 300 partially matching documents found.

Latest Intelligence

COVID-19 hits supply chains

During the Great Depression, this was called ‘yardstick capitalism’, Stoller noted, and it gives the government insight into proprietary data otherwise unobtainable.
Will biosimilars ever catch on in the US?

First-to-market generics included medicines for opioid overdose, pulmonary arterial hypertension, breast cancer, seizures, depression and various infections.
Healthcare trends 2020 – the biggest shifts changing lives and life sciences

Doctors across specialties are battling depression and burn-out as they continue to watch their roles and spheres of influence wholly shift.
Integrating patient reported outcomes into clinical trials

However, the HTA acknowledges the limitations of the index, noting that “the DLQI has limited validity in some people, and may miss anxiety and depression.”.
25 Women Leaders in UK Healthcare

In recent years she has also been outspoken about the pressures on doctors, highlighting the high levels of burnout, depression and suicide in the profession.

More from intelligence
Approximately 0 fully matching, plus 31 partially matching documents found.

Latest appointments

Clark Health Communications expands team

director in a role that will see her lead teams responsible for driving the delivery of CHC’s gastroenterology, women’s health, depression and anticoagulants business.
Dr Niall Murphy and Pierre Schwich join Pharnext

Prior to this, Dr Murphy served as a unit leader for a team of scientists collaborating on research in the areas of addition biology, Alzheimer's disease, anxiety, depression and neurotoxicity
Turing names Eliseo Salinas as head of R&D

Salinas has played a leading role in numerous programmes for a range of diseases and disorders, with specific focus on central nervous systems (CNS) condition such as depression and anxiety, schizophrenia,
Lundbeck promotes Andreas Eggert and Klaus Abel to senior commercial roles

vortioxetine for major depression and Selincro (nalmefene) for alcohol dependence. ... including a once-monthly aripiprazole formulation for the treatment of schizophrenia and brexpiprazole (OPC-34712) for the treatment of schizophrenia and major

More from appointments
Approximately 0 fully matching, plus 4 partially matching documents found.

Latest from PMHub

How does nature influence wellbeing and refocus the mind?

Asking too much of ourselves can lead to mental exhaustion and could be rapidly followed by anxiety, depression or sleepless nights.
The other side of … multiple sclerosis

Case in point – early on in her MS, she experienced depression, but didn’t think it relevant to discuss.
The Lucid Group Wellbeing Champions embark on their MHFA training

A mentally sound organisation is good for talent and business. Statistics from Mental Health First Aid (MHFA) England point out to mental health illness (such as depression or anxiety) accounting to
Oxford University Press

M for Media. “The book ‘Screening For Depression In Clinical Practice’ was well received, one of the highest response rates to a promotion in recent years.
July 2020: diversity and inclusion in clinical trials round-up

Stress and depression can disproportionately affect minority groups, and these can impact IBD symptoms and management.

More from PMHub
Approximately 5 fully matching, plus 32 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

Healthcare Lead Copywriter: Competitive

Medical Editor: Competitive

Account Manager Healthcare / Pharmaceutical Sector: Negotiable Salary

Healthcare Senior Account Manager: Competitive

Account Director – Creative Healthcare Communications: Competative

Healthcare Account Director: Competitive

Sales Director, Healthcare communications agency, London/ SE UK: Six figure salary

PMHub

Add my company

Branding Science

We are Branding Science Partners in thinking which inspires change in healthcare Branding Science are an award-winning global pharmaceutical market...

Latest intelligence

2020 - a year to remember or forget?: 2020 and the Covid pandemic brought immense challenges, and the need for change felt like it happened overnight. What have we learned and what does the future of agency working...
The search for effective drug treatments for COVID-19: PME talks to Julian Cole, Senior Director, Medical Affairs at Gilead Sciences...
AstraZeneca’s focus on diagnosing and managing chronic kidney disease: People living with chronic kidney disease are in urgent need of new and improved approaches to diagnosis and care...